McKesson director Bradley Lerman sells $268,589 in shares

McKesson’s Q1 fiscal 2027 results beat expectations, with adjusted EPS of $9.93 vs. $9.64 and revenue of $105.38B vs. $103.82B, prompting the company to raise its full-year earnings outlook. Wells Fargo lifted its price target to $933 from $812 while maintaining an Equal Weight rating, raising FY27–FY29 adjusted EPS estimates and projecting growth of 13.9% (FY27), 12.0% (FY28), and 12.1% (FY29). Offsetting this, a McKesson director (Bradley E. Lerman) sold 301 shares on Aug. 10 for about $268,589 and now holds no shares directly.

Analysis

The sale by a single director is not the signal here; the signal is that the business is still converting prescription throughput into earnings while the Street is incrementally revising numbers higher. For a low-margin distributor, volume is the real operating lever: even low-single-digit script growth can add disproportionate fee and spread dollars if mix stays favorable and working-capital discipline holds. That argues for continued relative strength in MCK, but not a straight-line rerating because the model remains exposed to reimbursement pressure and pass-through economics.

The bigger second-order read is the acceleration in mail-order share. That tends to concentrate demand into a smaller set of scale players and away from store-based pharmacy traffic, which is structurally negative for WBA and, to a lesser extent, the retail front-end at CVS. Over 1-3 months, the key catalyst is whether monthly script trends confirm that this is a durable channel shift rather than a one-off; over 6-18 months, higher mail-order penetration should support the largest-scale logistics and fulfillment platforms while compressing economics for fragmented pharmacy operators.

The contrarian point is that consensus may be overestimating how much of the volume tailwind drops to the bottom line. In distribution, more volume can still mean muted margin if mix shifts toward lower-spread generics or if manufacturers/payers push back on fees. The thesis breaks if prescription growth rolls over, if management stops raising guidance, or if policy headlines hit pharmacy reimbursement before the next earnings season.

Key Decisions for Investors

• Long MCK on pullbacks, holding into the next quarterly update; base case is continued EPS estimate drift higher, with downside primarily from reimbursement compression rather than demand. Use any post-earnings fade as entry.
• Pair trade: long MCK / short WBA for 1-3 months to express the channel-shift view. Favor the side with pricing power and scale over the side most exposed to store traffic erosion.
• If owning MCK outright feels rich after the recent run, use call spreads instead of stock to define risk; the setup is more of a steady compounding trade than a momentum squeeze.
• Watch CVS only as a nuance trade: omni-channel and PBM scale should cushion some of the mail-order shift, but a sustained move toward remote fulfillment is still a net headwind to the retail mix.